Avalo Therapeutics (AVTX) Other Non Operating Income (2020 - 2025)
Avalo Therapeutics' (AVTX) quarterly Other Non Operating Income came in at -$3000.0 in Q3 2025, up 40.0% YoY from -$2142.9 in Q3 2024, and up 40.0% on a QoQ basis from -$5000.0 in Q2 2025.
Powered by 
Analysis
Avalo Therapeutics (AVTX) Other Non Operating Income (2020 - 2025) Analysis & Trends
Avalo Therapeutics (AVTX) has 5 years of Other Non Operating Income data on file, last reported at -$3000.0 in Q3 2025.
- Quarterly Other Non Operating Income rose 40.0% year-over-year to -$3000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$13000.0 (up 89.6% YoY) and the FY2024 annual result came in at -$5000.0, up 88.1% from the prior year.
- Other Non Operating Income rose to -$3000.0 in Q3 2025, from -$5000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of -$3000.0 in Q3 2025 to a low of -$180000.0 in Q1 2023.
- A 4-year average of -$43750.0 and a median of -$10000.0 in 2021 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2021 — Other Non Operating Income slumped 178.95% — and 2024, when it jumped 70.59%.
- Tracing AVTX's Other Non Operating Income over 4 years: stood at -$15000.0 in 2021, then declined by 13.33% to -$17000.0 in 2023, then surged by 70.59% to -$5000.0 in 2024, then jumped by 40.0% to -$3000.0 in 2025.
- The last three Other Non Operating Income figures came in at -$3000.0 (Q3 2025), -$5000.0 (Q2 2025), and -$5000.0 (Q3 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Avalo Therapeutics | 838.47 Mn | 838.47 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -3,000.00 |
| Jun 30, 2025 | -5,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Mar 31, 2024 | -120,000.00 |
| Dec 31, 2023 | 78,000.00 |
| Sep 30, 2023 | 100,000.00 |
| Jun 30, 2023 | -40,000.00 |
| Mar 31, 2023 | -180,000.00 |
| Mar 31, 2022 | -20,000.00 |
| Sep 30, 2021 | -15,000.00 |
| Jun 30, 2021 | -5,000.00 |
| Dec 31, 2020 | -38,000.00 |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | 398,000.00 |
| Mar 31, 2020 | 11,000.00 |